News from orexo A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.
Latest
Sep 25, 2020, 08:20 ET Invitation - Orexo Digital Therapeutics business update October 1
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts, and media to attend a teleconference on Thursday October 1, at 3 pm...
Sep 14, 2020, 08:02 ET Orexo commences patent infringement litigation against Sun Pharmaceutical
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces it has filed a patent infringement action in the United States District Court for the...
Sep 09, 2020, 11:14 ET Orexo and GoGoMeds Partner to Bring Digital Therapies to Populations Battling Addiction and Depression with Limited Support Options
Orexo and GoGoMeds have formed a partnership to make the scientifically-proven, digital therapies deprexis® and vorvida® available for the treatment...
Sep 01, 2020, 08:22 ET Orexo and Lyfebulb Announce the Finalists and Jury for the 2020 Innovation Challenge in Substance Use Disorders
Orexo, a Swedish pharmaceutical company focused on improved pharmaceuticals and digital therapies, and Lyfebulb, a patient empowerment platform,...
Aug 10, 2020, 02:09 ET Orexo receives paragraph IV Notice Letter for ZUBSOLV® in the US
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces it has received a "paragraph IV" patent certification notice from Sun Pharmaceutical...
Jul 16, 2020, 02:17 ET Orexo Interim Report Q2 2020
Investing in diversification to drive future growth Q2 2020 highlights Total net revenues of SEK 179.1 m (201.2) EBITDA of SEK -9.0 m (60.4),...
Jul 02, 2020, 02:34 ET Orexo Launches Deprexis® and Vorvida® in the US and Provides Updated Financial Guidance
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) announces today the US launch of the scientifically proven digital therapies deprexis® and vorvida®, for...
Jun 30, 2020, 02:28 ET Positive Results from Human PK Study Assessing Orexo's Intranasal Nalmefene Formulations for Opioid Overdose Reversal
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces positive results from its human pharmacokinetic (PK) study of OX125. The study was a...
Jun 17, 2020, 08:17 ET Orexo and Lyfebulb Announce Call for Digital Solutions to Treat Substance Use Disorder
Orexo, a Swedish pharmaceutical company focused on improved pharmaceuticals and digital therapies, and Lyfebulb, a patient empowerment platform,...
May 29, 2020, 11:46 ET Number of Shares and Votes in Orexo
The number of shares and votes in Orexo AB (publ.) has changed as a result of the cancellation of 842,971 class C shares, which was resolved at the...
May 19, 2020, 07:16 ET Report From Orexo AB's Extraordinary General Meeting, 19 May 2020
Today on 19 May 2020, Orexo AB (publ) held an extraordinary general meeting. The extraordinary general meeting passed the following resolutions....
May 18, 2020, 08:17 ET Orexo and Lyfebulb Partner During Unprecedented Times to Help Those Struggling With Alcohol and Opioid Use Disorders
Orexo, a Swedih pharmaceutical company focused on improved pharmaceuticals and digital therapies, announced that it will partner with Lyfebulb, a...
May 15, 2020, 04:54 ET Orexo's Partner Gesynta Pharma Announces Positive Results from Phase 1 Study for OX-MPI
Orexo's partner, Gesynta Pharma, today announces positive phase I results for OX-MPI (GS-248). Gesynta Pharma, who owns all the rights to OX-MPI...
May 11, 2020, 02:24 ET Orexo Acquires Exclusive US Rights to Commercialize deprexis®, A World-leading Digital Therapy to Help Patients Manage the Symptoms of Depression
Orexo AB (publ.) today announces it has acquired the exclusive US rights to GAIA AG's (GAIA) deprexis®, a digital therapy to help patients manage...
Apr 28, 2020, 02:46 ET Orexo Presents the Interim Report for Q1 2020
Q1 2020 highlights Total net revenues of SEK 175.0 m (174.3), up 0.4 percent EBITDA of SEK 39.1 m (12.0), up 225.8 percent Net earnings of SEK 82.6 m ...
Apr 16, 2020, 13:56 ET James Noble Appointed as Chairman of the Board
Orexo AB (publ.) today announces the appointment of James Noble as Chairman of the Board. The resolution was taken today at the annual general...
Apr 16, 2020, 13:07 ET Notice of Extraordinary General Meeting of Orexo
The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the extraordinary general meeting, to be held...
Apr 16, 2020, 12:25 ET Report from Orexo's Annual General Meeting, 16 April 2020
Election of the board of directors and auditor The annual general meeting in Orexo AB (publ) on 16 April 2020 resolved, in accordance with the...
Apr 09, 2020, 11:39 ET The Board of Directors of Orexo Withdraws Proposal on Incentive Program
The board of directors of Orexo AB (publ) has resolved to withdraw the previously communicated proposals to the annual general meeting 2020...
Apr 06, 2020, 02:12 ET Orexo Ends Share Buy-back Program
Orexo AB (publ) has ended the program to repurchase its own ordinary shares that was announced on February 17, 2020. A total of 500,000 shares,...
Mar 26, 2020, 09:15 ET Orexo Publishes the Annual Report for 2019
Annual Report, including the Sustainability Report, for the 2019 fiscal year has been published. The Annual Report can be downloaded on the company's ...
Mar 25, 2020, 16:52 ET Orexo Has Repurchased 14 Percent of Own Corporate Bonds
Orexo AB (publ.) has repurchased 14 percent of its outstanding unsecured corporate bonds with a nominal value of SEK 40,500,000 through several...
Mar 17, 2020, 03:34 ET Orexo Presents Sales Potential of the Pharmaceutical Pipeline and Digital Therapies During the Capital Markets Day
Orexo AB (publ.), today hosts a Capital Market Day in Stockholm, Sweden. On the day the company will present an overview of the company's growth...
Mar 16, 2020, 16:05 ET Notice of Annual General Meeting of Orexo
The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on...
Mar 12, 2020, 13:08 ET Invitation to Attend Orexo's Capital Markets Day via Teleconference
As previously communicated, Orexo invites investors, analysts and the media to participate in the company's Capital Markets Day in Stockholm, Sweden, ...
